Rahul Winayak, MD, explains new mRCC targets—GPR65, HPK1, ENPP3, CD70—that aim to overcome immunotherapy resistance.
Rahul Winayak, MD
Advertisement
Articles by Rahul Winayak, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Late-Breaking Phase 3 Data Headline ESMO 2026 Presidential Symposium I
2
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
3
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
4
Sunvozertinib Now Available in US for EGFR Exon 20 Insertion NSCLC
5